CTOs on the Move

Bonna-Agela Technologies

www.bonnaagela.com

 
Bonna-Agela Technologies is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Epredia

Improving lives by enhancing precision cancer diagnostics.

Scout.com Inc

Scout.com Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ambys

Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals with $140M in starting capital and is headquartered in South San Francisco, Calif.

Antibe Therapeutics

Antibe Therapeutics develops safer medications for chronic pain and inflammation. Today, physicians and consumers rely principally on non-steroidal anti-inflammatory drugs (NSAIDs), a $12 billion category of medications that includes brands like Advil, Aleve, Motrin, Celebrex, Voltaren and Aspirin. While effective, NSAIDs can cause gastrointestinal damage and bleeding. To address this serious medical need, Antibe has patented a technology for linking NSAID molecules to hydrogen sulfide molecules. More than a decade of academic and applied research has demonstrated that hydrogen sulfide, when appropriately delivered, can protect the gastrointestinal tract and enhance the anti-inflammatory effectiveness of today’s NSAIDs. Beginning with its IPO in mid-2013, Antibe has raised more than $10 million and initiated human clinical trials of its first drug, aimed at mild to moderate pain.

Alpine Immune Sciences

Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat autoimmune and inflammatory diseases. We have two products in the clinic for inflammatory diseases, collaborations with world-class partners, and a robust development pipeline. Traded on NASDAQ under ticker ALPN.